Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: www.sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

cea Feb. 4 at 6:46 PM

$SLS Read and heed. Good post @Bless_immuno

0 · Reply

Bayside1983 Feb. 4 at 6:45 PM

$SLS this is normal accumulation after run up.

0 · Reply

zyskowiedza Feb. 4 at 6:45 PM

$SLS Sterg winks at us. You'd have to be stupid not to notice. And although it's currently working against us, both he and we know it will ultimately benefit us.

0 · Reply

Rolo2024 Feb. 4 at 6:45 PM

$SLS Yawn! Bought more under $3.80 so tasty!

0 · Reply

Bretm50 Feb. 4 at 6:44 PM

$SLS Oversold!

0 · Reply

ScienceBling Feb. 4 at 6:44 PM

$SLS Hence the CONFIDENCE GAME; not only the Shorties but also the all ACCUMULATORS want your shares as cheaply as feasible. Billions to win!!!

1 · Reply

Fishbanger51 Feb. 4 at 6:44 PM

$SLS my interpretation of sterg messages...generational wealth potential

0 · Reply

BimmernutZ Feb. 4 at 6:42 PM

$SLS Did it go below -10% to trigger SSR?

0 · Reply

BiotechnicallyRetarded Feb. 4 at 6:41 PM

$SLS drop us lower and give us SSR, screw it...

0 · Reply

zyskowiedza Feb. 4 at 6:40 PM

$SLS We don't need to say anything. Normal moves dog😂 Waiting till 80/BO. If u don't understand just go to normal job bcs u wasting your last few braincells

1 · Reply

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Dec 29, 2025, 8:35 AM EST - 5 weeks ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 2 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Oct 29, 2025, 5:36 PM EDT - 3 months ago

SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript

Oct 27, 2025, 8:30 AM EDT - 3 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Aug 19, 2025, 9:18 PM EDT - 6 months ago

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

Aug 7, 2025, 8:30 AM EDT - 6 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 7 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 8 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 8 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 9 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 9 months ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 9 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 10 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 10 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 10 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 31, 2025, 3:03 PM EDT - 11 months ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 20, 2025, 4:05 PM EDT - 11 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 1 year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 19, 2024, 1:49 PM EDT - 1 year ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Mar 28, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:35 AM EDT - 2 years ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 2 years ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 2 years ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 2 years ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 2 years ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Feb 6, 2024, 8:30 AM EST - 2 years ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

cea Feb. 4 at 6:46 PM

$SLS Read and heed. Good post @Bless_immuno

0 · Reply

Bayside1983 Feb. 4 at 6:45 PM

$SLS this is normal accumulation after run up.

0 · Reply

zyskowiedza Feb. 4 at 6:45 PM

$SLS Sterg winks at us. You'd have to be stupid not to notice. And although it's currently working against us, both he and we know it will ultimately benefit us.

0 · Reply

Rolo2024 Feb. 4 at 6:45 PM

$SLS Yawn! Bought more under $3.80 so tasty!

0 · Reply

Bretm50 Feb. 4 at 6:44 PM

$SLS Oversold!

0 · Reply

ScienceBling Feb. 4 at 6:44 PM

$SLS Hence the CONFIDENCE GAME; not only the Shorties but also the all ACCUMULATORS want your shares as cheaply as feasible. Billions to win!!!

1 · Reply

Fishbanger51 Feb. 4 at 6:44 PM

$SLS my interpretation of sterg messages...generational wealth potential

0 · Reply

BimmernutZ Feb. 4 at 6:42 PM

$SLS Did it go below -10% to trigger SSR?

0 · Reply

BiotechnicallyRetarded Feb. 4 at 6:41 PM

$SLS drop us lower and give us SSR, screw it...

0 · Reply

zyskowiedza Feb. 4 at 6:40 PM

$SLS We don't need to say anything. Normal moves dog😂 Waiting till 80/BO. If u don't understand just go to normal job bcs u wasting your last few braincells

1 · Reply

CEOofstocks Feb. 4 at 6:39 PM

$SLS want some perspective? 2 months ago, this was $1.39. Let that sink in.

0 · Reply

OnTheBalance Feb. 4 at 6:38 PM

$SLS Some tough love here... BLOCK ME if you don't like it.. I don't care :)))))).. ALL SHARES ALWAYS HAVE AN OWNER. This is what I believe is the CEO's deeper message.. read the second paragraph in his post carefully. He is addressing all shareholders and telling them the Company is being BOUGHT... 13 FTE's. But he doesn't care if scared or impatient retail sell their shares now so that FAMILY OFFICES, PRIVATE WEALTH and OTHER somewhat Bigger retail entities can buy those shares now. On LinkedIn he has over 9000 followers. Several appear to be connected to "money management". i don't mean the biggies.. but Private Wealth.. that can buy/own 500K shares or more comfortably, without breaking much sweat. He has said enough.. MAJOR INFLECTION POINT... Pivotal Moment.. my take... BOD is engaged with BPs Good Luck Investing.. but stop whimpering, stay or leave.

0 · Reply

Darkhorse34 Feb. 4 at 6:38 PM

$SLS “We are seeing a meaningful survival benefit over standard of care - [ typically 8 months] “ The go in between CEO LinkedIn statements. Statistical win, biologically real, but not a smash.

0 · Reply

mchansen7 Feb. 4 at 6:38 PM

$SLS this price action is truly a gift, accumulate!

0 · Reply

SunnySeed Feb. 4 at 6:37 PM

$SLS SSR then PR tomorrow

0 · Reply

LionTrader4508 Feb. 4 at 6:37 PM

$SLS Bought 4k more thanks for the cheapies..

0 · Reply

jacksparo Feb. 4 at 6:36 PM

$SLS $IBRX The market is putting a big pressure into most of the indexes! Nothing can be done here. Some people will sell and leave, others will stay! Have a plan and a budget the best thing to do!

0 · Reply

rpc630 Feb. 4 at 6:35 PM

$SLS 1 step forward and 3 steps back!!

0 · Reply

JuggernautRaider Feb. 4 at 6:34 PM

$SLS $CCCC $TLSA $ALT biotech is selling off for no good reason while big pharma is BOOMING… a natural buying opportunity 💎 👊

0 · Reply

Warrens__Buffet_ Feb. 4 at 6:34 PM

$SLS down 40 cents today bulls what do you have to say for yourselves?

1 · Reply

jumptime Feb. 4 at 6:34 PM

$SLS My whole screen is blood red...

0 · Reply

rpc630 Feb. 4 at 6:33 PM

$SLS Like I said earlier Nice signal. Each time down 15%.

0 · Reply

Market Cap	537.01M
Revenue (ttm)	0.00
Net Income (ttm)	-30.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,859,600
Avg Vol	8,978,764
Day's Range	N/A - N/A
Shares Out	142.44M
Stochastic %K	42%
Beta	2.26
Analysts	Strong Sell
Price Target	$6.83